The MarketWatch News Department was not involved in the creation of this content. -- 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level -- ...
(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial. The SPECTRA trial is ...
4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema (DME) and sending its stock up more than 40% in premarket trading. The ...
EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic ...
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback